Leqembi

News

Australia joins EU in turning down Alzheimer's drug Leqembi

Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy Leqembi, saying its efficacy does not outweigh its risks.

News

UK first country in Europe to clear Leqembi, but NICE says n...

The UK drugs regulator has approved Eisai and Biogen's Alzheimer's disease therapy Leqembi, shortly after an EU committee turned it down on the grounds that its modest efficacy did not outw

News

After EU setback, Eisai/Biogen build case for Leqembi

Eisai and Biogen have reported data showing that the benefit of treatment with their Alzheimer's disease therapy Leqembi appears to build over time, with no increase in safety risks.

News

In shock move, EU panel rejects Alzheimer's drug Leqembi

The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China, and Japan gave a green lig

News

Lilly gets FDA OK for Alzheimer’s drug, cites cost advantage

Eli Lilly finally has FDA approval for its amyloid-busting Alzheimer’s disease therapy donanemab and will launch it at a cost it claims could deliver savings compared to a rival therapy fro

News

Lilly’s Alzheimer’s drug set to join Leqembi after FDA vote

An FDA advisory committee has delivered a strong endorsement to Eli Lilly’s Alzheimer’s disease therapy donanemab, voting unanimously that the safety and efficacy of the amyloid-busti

Australia joins EU in turning down Alzheimer's drug Leqembi

UK first country in Europe to clear Leqembi, but NICE says n...

After EU setback, Eisai/Biogen build case for Leqembi

In shock move, EU panel rejects Alzheimer's drug Leqembi

Lilly gets FDA OK for Alzheimer’s drug, cites cost advantage

Lilly’s Alzheimer’s drug set to join Leqembi after FDA vote

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Leqembi

Editor's Picks